Theofilou and Panagiotaki: A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients

A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients

Abstract

Adherence to medication has been recognized as a key issue in health outcomes and efforts to improve patients' adherence are being made by the pharmaceutical industry, experts, and government bodies alike. This paper presents a review of these issues according to previous descriptive findings. Relevant studies written in English, published in 1976 or later, were identified through Medline, Embase and PsycInfo databases and reviewed. Review articles and clinical trials were excluded; all observational studies and surveys were considered. Articles were reviewed for any discussion of patients' characteristics and psychosocial characteristics affecting adherence to cancer treatment. The search strategy included a combination of key words adherence and cancer in titles. The major findings are summarized and presented under two main headings: i) patients' characteristics; and ii) psychosocial characteristics. In general, factors associated with increased likelihood of adherence to cancer treatment included younger age, higher education, higher income and Caucasian ethnicity. With regards to the psychosocial factors, lower levels of depression and anxiety, optimism as well as social support seemed to have a positive effect on treatment adherence. Studies of patterns of care in cancer treatment can help identify challenges in health care provided to particular subgroups of cancer patients and can aid researchers in designing studies that account for such factors in clinical and outcomes' research.




Introduction

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries.1,2 The burden of cancer is increasing in economically developing countries as a result of population aging and growth as well as, increasingly, an adoption of cancer-associated lifestyle choices, including smoking, physical inactivity, and westernized diets. With the increasing development and marketing of therapies for cancer, including the recent explosion in small molecule inhibitors that have either already been approved by the US Food and Drug Administration or are being examined in ongoing clinical trials, the issue of patient adherence has gained importance for the oncology community.3

According to the World Health Organization (WHO), adherence is a person's behavior concerning taking medication, following a diet, and making changes in lifestyle in accordance with a medical or non-medical health professional recommendations.4 Thanks to the large body of research published over recent decades, several factors have been identified with regard to their influence on adherence behavior.5,6 So far, it has been difficult to decide which factors are of the most significance and how these interact in influencing adherence behavior.7 The WHO has structured recognized influential factors into five dimensions: social/economic, therapy-related, patient-related, conditionrelated and those related to the health-care team and system.4 Key reasons for non-adherence include adverse effects or other problems with medications, such as poor instructions, poor memory, inability to pay for medications, disagreement about the need for treatment, and poor relationships between consumers and healthcare professionals.810 Other reasons for non-adherence include polypharmacy,11 low literacy, 12 silent conditions such as hyperlipidemia, hypertension and osteoporosis, 13 cultural factors,14 inadequate social support,15 depression, 16,17 health beliefs18,19 or patientsi personality.20

A review of the research into cancer therapy and patient adherence showed that it has mainly focused on non-adherence to taking chemotherapy medication and attending medical appointments, whereas there is very little research on adherence for other behavioral aspects of therapy (e.g. fluid intake, weight maintenance, etc.) that are relevant across all cancers. Some studies have examined adherence to certain behavioral aspects for a specific cancer (e.g. adherence to toothpaste or gel fluoride treatment for head and neck cancers).21 However, the prevalence and assessment of non-adherence to a wide range of behavioral aspects common across all cancers has not been extensively examined. Because of their importance in promoting patient health and quality of life (QoL), these aspects deserve further attention.

Numerous studies have examined the factors affecting how cancer patients receive treatment but for the moment there is no literature available that compiles factors associated with patients' characteristics and psychosocial characteristics in a single source. For example, it is commonly understood that older patients are generally less likely to receive cancer treatment due to their shorter life expectancies, general poorer health and the reduced risk/benefit. However, other factors may also influence receipt of treatment, even in younger patients, and need to be accounted for in observational studies and research into outcomes involving cancer. Therefore, we performed a review of the literature and information published since 1976 regarding the factors affecting treatment adherence in patients with cancer, taking into account patients' characteristics and psychosocial characteristics.

Materials and Methods

Published data assessing adherence in cancer patients from the past 35 years (from 1976 to 2010) was searched for in Medline, Embase and PsycInfo databases including the following terms: adherence, cancer, psychosocial characteristics and patient characteristics. Review articles, case reports and clinical trials were excluded; observational, clinical, and population-based studies were considered, as were survey data of physicians and oncologists. General clinical reviews that provided treatment guidelines but no original data were also excluded. The factors studied in relation to receipt of cancer treatment were roughly divided into two primary categories: patients' characteristics and psychosocial characteristics.

In order to have a more integrated view on the topic of adherence, we have also reported some results concerning the adherence in a more general context, that is the field of chronic diseases other than cancer.

Results and Discussion

Several variables have been found to be associated with adherence to cancer treatment. Some commonly cited variables are education,22 income,22 emotional states2325 and complexity of the treatment regime.26 In addition, optimism has been found to be associated with adherence to medication taking,27 but has not been examined with adherence to cancer treatment regimens. The relevant studies that have examined the patient and psychosocial variables in relation to adherence are summarized below.

Patients' characteristics

Age

Most of the studies showed that age was related to adherence in chronic diseases, although a few researchers found age not to be a factor causing non-adherence.2831 For elderly people, the results from the various studies are not unidirectional. A large proportion of retrieved studies suggested that they might have higher adherence.3245 However, in contrast, some studies found that advancing age affected adherence among elderly people in a negative way.4648 Regarding cancer treatment, all of the studies examined found that older patients received chemotherapy showed less adherence than younger patients.4957 Of these studies, 7 provided numerical data to support this conclusion.5054,56,57 Five of the studies demonstrated a statistically significant difference in chemotherapy use between older and younger patients,5154,56 although only 2 of these provided data specific to metastatic cancer.52,53 In a prospective survey of qualified specialists in France, the authors noted that, of the women receiving chemotherapy, 82% in the younger age group received the standard dose and cycle length compared with only 62% of those in the older age group.53 In a survey administered to medical and clinical oncologists in the UK, asking which factors were important in deciding whether to recommend chemotherapy to patients with metastatic breast cancer, patient age was considered to be quite important or very important for 58.6% of oncologists surveyed.58

Several studies offered reasons to explain why older women were less adherent to chemotherapy. The lower proportion of older women with breast cancer receiving chemotherapy may reflect an increased number of co-morbidities and worse general health among these women.53 For example, among British oncologists, frailty and concurrent medical conditions were considered quite important or very important to 93.1% and 82.8% of surveyed clinicians, respectively, compared to the 58.6% of oncologists who considered age to be of importance.58 Of the 10 studies in this review citing the impact of age on chemotherapy use, only two adjusted for co-morbidities,51,52 one of which18 provided data specific to metastatic breast cancer. In both studies, multivariate analyses revealed a stronger inverse association of increasing age and chemotherapy use than that of co-morbidity and chemotherapy use. The higher prevalence of hormone receptor (estrogen or progesterone receptor) positive tumors among postmenopausal women than premenopausal women59 and, therefore, more frequent use of hormone therapy, also contributes to this observation. It has been suggested that elderly patients have cancers with lower proliferative indices, and that they will derive less benefit from standard chemotherapy;60 however, the elderly are frequently underrepresented in cancer clinical trials. Although elderly (65 years of age or older) patients make up 63% of cancer patients in the US, they represent only 25% of the cancer clinical trial participants.61 Whether this deficit is due to fear and misunderstanding of older patients, physician bias against enrolling older patients, or overly stringent eligibility criteria that limit the number of elderly patients, their underrepresentation makes it difficult to assess the risks and benefits of cancer chemotherapeutic regimens and may partially explain the inverse relationship between age and chemotherapy use. Also, elderly patients may have problems in vision, hearing and memory. In addition, they may have greater difficulty in following therapy instructions due to cognitive impairment or other physical difficulties, such as having problems in swallowing tablets, opening drug containers, handling small tablets, distinguishing colors or identifying markings on drugs.6269

Education

Several studies found that better educated patients might have higher adherence,7072 while some studies found no association.7378 Intuitively, it may be expected that patients with higher levels of educational should be better informed about the disease and therapy and, therefore, demonstrate greater adherence. However, Di Matteo found that even highly educated patients may not understand their medical condition or may not perceive the benefits of adherence to their medication regimen.79 Other researchers showed that patients with lower levels of education show better adherence.80 Four studies discussed education level in relation to chemotherapy treatment,81,58,55,56 as well as other adjuvant therapies, such as radiation and hormone therapy; only 2 provided quantitative data related to chemotherapy,82,55,56 and only one was specific to metastatic breast cancer.58 Peele and colleagues stated that educated women were significantly more likely to adhere to treatment with adjuvant therapy, including chemotherapy, hormone therapy, and combination therapy, although the study did not distinguish between cases based on disease severity and treatment.56 Mitchell and colleagues reported that being less educated was statistically significantly and inversely correlated to a belief in religious intervention in place of treatment;55 it is presumed that the treatment likely included chemotherapy due to inclusion of women with advancedstage breast cancer in the study population. From a qualitative perspective, Ashing-Giwa and colleagues, when discussing various adjuvant therapies including chemotherapy, reported that less-educated women in the United States were less informed about breast cancer itself, as well as about resources and treatments. They were less adherent to treatment and less proactive in seeking medical care.81 In the UK, 13.8% of clinicians ranked education as an important factor influencing their recommendation for palliative chemotherapy to women with metastatic breast cancer.58

Cost of therapy and income

Cost is a crucial issue in patient adherence especially for patients with chronic disease as treatment could be life-long.8386 Healthcare expenditure could be a large portion of living expenses for patients suffering from chronic disease. Cost and income are two interrelated factors. Healthcare cost should not be a heavy burden if the patient has a relatively high income or health insurance. A number of studies found that patients who had no insurance cover,8789 or who had low income,9095 were more likely to be non-adherent to treatment. However, even for patients with health insurance, health expenses could still be a problem. More than one in 10 senior citizens in the USA reported using less of their required medications because of cost.96 Nevertheless, in other cases, income was not related to adherence level.97100 Three studies discussed income in relation to chemotherapy treatment: 2 in the US101 and one in the UK.102 Of the 2 studies that provided numerical data, neither observed a significant difference in the proportions of patients receiving chemotherapy by income, although one suggested that their observation that uninsured, lower income women were less likely to adhere to chemotherapy may have reached statistical significance with a larger sample size. A qualitative study of community health professionals working with different patient populations reported that individuals with lower income may not have sufficient awareness of the disease, resources, and treatments, and are not as proactive about seeking medical care.

Ethnicity

Race as a factor causing non-adherence has been studied fairly widely in the USA and European countries. Caucasians are believed to have good adherence according to some studies,103106 while African- Americans, Hispanics and other minorities were found to have comparatively poor adherence.107113 However, a plausible explanation for this may be due to the patients' lower socio-economic status and language barriers affecting the minority ethnic races in the study countries. Hence, due to these confounding variables, ethnicity may not be a true predictive factor of poorer adherence. Five studies, all conducted in the US, considered race to be a factor in predicting adherence to chemotherapy in breast cancer patients.52,55,81,114,115 Only one study presented data specific to metastatic breast cancer,52 with the remainder considering all cases (stages I through IV) in aggregate. In a study by Du and Goodwin,52 the proportions of black and white women with stage IV breast cancer who received chemotherapy were similar (26.8% vs. 26.5%, respectively), although fewer women whose race was classified as other received chemotherapy (18.2%). Two other studies (not specific to stage IV disease) reported very small differences in the percentages of Caucasian, African-American, and Hispanic women with breast cancer treated with chemotherapy; both noted that higher proportions of Caucasian women (81.3% and 67.0%) than African-American women (80.0% and 46.5%) or Hispanic women (52.4%) received chemotherapy, 114,115 although these differences either were not statistically significant or statistical significance was not evaluated.115

Psychosocial characteristics

Emotional states: depression, anxiety and adherence

Research has indicated that emotional states such as depression and anxiety may be associated with adherence. A recent meta-analysis conducted across medical regimens by Di Matteo, Lepper, and Crogham116 reported that depressed patients were 3 times as likely as non-depressed patients to be non-adherent, but found that anxiety was not significantly associated with adherence. A few studies on cancer therapy regimens have examined the relationship between emotional states and adherence. For example, Ayres et al.117 prospectively examined psychosocial aspects in order to predict adherence to administered chemotherapy appointments for grade IV cancer. Using discriminant analysis, patients who exhibited more anxiety and depression were more likely to adhere by attending chemotherapy appointments. Furthermore, Richardson et al.24 found that depression at six months was significantly correlated with non-adherence in patients who took oral chemotherapy medication intermittently. Finally, Itano et al.23 found that those with higher state anxiety were more likely to adhere to attending chemotherapy and blood laboratory work appointments.

In summary, most research indicates that depression plays an important part in predicting non-adherence. From a conceptual standpoint, it can be postulated that depression may affect cognitions (e.g. outcome expectancies, perceived benefits and barriers) and motivation to follow through with treatment recommendations. However, the role that anxiety plays with regard to adherence is less clear. Across medical regimens, research has indicated that anxiety has had no significant effect on adherence. However, some of the research into cancer and adherence has indicated that anxiety is positively correlated with adherence. Some have argued that anxiety can be associated with enhanced adherence because anxious individuals have been shown to be more hypervigilant and have an increased tendency to seek medical assistance.118

Optimism and adherence

Optimism has been found to predict a better QoL119 and promote lower distress levels among breast cancer patients.120 With regard to adherence, some research has indicated that optimism is associated with a more positive attitude toward medication taking.121 Carver, Lehman and Antoni122 argued that optimism keeps patients involved and engaged in treatment goals, leading to an improved psychological well-being. It also seems likely that optimistic patients focus on positive aspects of treatment, or benefits, and are more likely to adhere.

Social support/partners

The general findings from these articles showed that patients who had emotional support and help from family members, friends or healthcare providers were more likely to be adherent to the treatment.123133 The social support helps patients in reducing negative attitudes to treatment, being motivated and also remembering to implement the treatment. Two studies provided numerical data regarding the impact of a spouse or significant other on the adherence to chemotherapy treatment52,82 one of which provided data specific to metastatic breast cancer.52,18 Osborne et al. reported that married women were more likely to adhere to chemotherapy than unmarried women (married 12.3% vs. unmarried 9.1%). Du and Goodwin also reported similar findings (married 37.4% vs. unmarried 20.7%). One study suggested that unmarried women might receive chemotherapy less often due to patients' personal concerns over postoperative assistance and transportation or the amount of out-of-pocket expense for treatment, or due to a doctor's decision not to discuss such treatment options because of these assumptions.82 Of British clinicians surveyed, 51.7% reported that the patient's social support was an important factor in their decision to give palliative chemotherapy to women with metastatic breast cancer.58

Details of studies included in the review are listed in Table 1.

Table 1

Details of the studies included in the review.

Study Type of study Patients Age (years) Statistical analysis Factors of adherence
Caban et al.49 Population-based 234 56 (range 2486) Hierarchical Logistic Regression Age
Diab et al.50 Study population 307.115 55 Linear Associations Age
Du et al.51 Population-based 35.060 65 Multivariate analysis Age
Du et al.52 Study population 1.129 65 Logistic regression Age, ethnicity, social support
Freyer et al.53 Prospective survey 1.009 500 from 65 to 74 (average 68.6) and 509 >75 (average 79.6) Correlation Age
Golledge et al.54 Study population 784 60 Correlation Age
Mitchell et al.55 Clinical 682 40 Factor analysis Age, education, ethnicity
Peele et al.56 Clinical 386 Not stated Not stated Age, education
Wyld et al.57 Clinical 378 5569 and >70 (comparative study) Statistical significance tested with 2 Age
Dunnwald et al.59 Population-based 155.175 30 Multivariate Cox regression modelling Age
Hutchins et al.61 Population-based 16.396 >65 Two-tailed P values Age
Benner et al.62 Retrospective cohort 35.401 >65 Generalized linear models for repeated measures Age
Chizzola et al.63 Clinical 485 54 (range 1786) Chi-square test, students t-test, multivariate log-line or regression analysis Age
Theofilou64 Clinical 168 62 Independent-samples t-test, one-way ANOVA, correlation Age
Jeste et al.65 Clinical 110 Not stated Stepwise regression analysis Age
Murray et al.66 Clinical 140 Not stated Not stated Age
Nikolaus et al.67 Clinical 119 Not stated Not stated Age
Okuno et al.68 Clinical 220 60 (mean age of 75.7) Multiple logistic regression analysis Age
Ashing-Giwa et al.81 Clinical 102 Not stated Not stated Education, ethnicity
Osborne et al.82 Population-based 32.268 65 Not stated Education, social support
Liu et al.101 Population-based 13.703 Not stated Logistic regression Income
Downing et al.102 Population-based 12.768 Not stated Logistic regression and Cox proportional hazards analyses Income
Maloney et al.114 Clinical 52 56.6 Chi-squared and tailed t-tests Ethnicity
Shavers et al.115 Epidemiology 3.978 2134 Multivariate analyses Ethnicity
Richardson et al.24 Clinical 92 1886 Not stated Emotional states
Carver et al.119 Clinical 163 Not stated Correlation and multivariate analyses Optimism
Epping-Jordan et al.120 Clinical 80 Not stated Regression analyses Optimism
Godin et al.121 Clinical 376 Not stated Regression analyses Optimism
Carver et al.122 Clinical 235 27 to 87 (mean age of 53.59) Regression coefficients Optimism

[i] ANOVA, analysis of variance.

Conclusions

In this review, we attempted to identify general factors related to adherence. Original studies investigating adherence in cancer patients were retrieved. However, in order to have a more integrated view on the specific topic, we have also reported some results from different diseases, population settings and different countries. In the process, we identified a wide array of influencing factors. Although the effect of some factor on adherence is complex and not unequivocal, the review process has identified several factors with consistent impact on adherence. Factors affecting receiving treatment in patients with cancer have been well studied, but for the moment there is no literature available that compiles factors associated with patients' characteristics and psychosocial characteristics in a single source.

The effect of demographic factors (e.g. age, ethnicity and educational level) on adherence is complicated by the fact that they may not be truly independent. In fact, demographic factors are related to patient cultural, socioeconomic and psychological backgrounds. Thus, future studies on adherence should not focus on demographic factors alone. Psychosocial factors such as psychological well-being, social support, patients' beliefs and their motivation regarding therapy could be classified as crucial factors. Since the 1990s, research has focused more on the patient-provider relationship, patient's mental health and patient's beliefs about their therapy. For individuals with chronic diseases, and specifically in cancer patients, a favorable quality of life would enhance their treatment adherence. In fact, the effects of patient's beliefs, emotional states, health knowledge and relationship with the healthcare provider are very complex because these factors are interrelated with each other. The interaction is a little like antibiotic combinations. Sometimes the effect is additive or synergistic while other times the effect is antagonistic. However, due to the design of the studies performed so far, it is difficult, if not impossible, to differentiate precisely between whether the interaction between these factors has been additive, synergistic or antagonistic. More robust and better designed studies would be needed in future to clarify these interactions. Certainly, there are some limitations in the current review. Three electronic databases, Medline, Embase and PsycInfo, were searched and only English articles were included. It might be possible that some informative studies in other literature databases or in other languages were omitted. Also, from the review of the literature starting from the 1970s to identify relevant factors relating to therapeutic adherence, the evidence indicates that non-adherence is still commonplace and no substantial change has occurred despite the large number of studies attempting to address and highlight the problem. In addition, too few studies are being carried out systematically to quantify the impact of non-adherence on health and financial outcomes. The magnitude of the impact of non-adherence needs to be studied in future research due to the potentially enormous implications of poor adherence on clinical and economic outcomes. Finally, few studies on adherence have been performed in Asia and developing countries where most of the world's population now lives. More studies on factors influencing adherence in these countries or regions would be helpful to fill the gap in our knowledge and help formulate international strategies to reduce non-adherence.

References

1 

World Health OrganizationThe Global Burden of Disease: 2004 UpdateGenevaWorld Health Organization2008

2 

P TheofilouQuality of life outcomes in patients with breast cancerOncology Reviews20126e2e2

3 

S De Geest, E SabateAdherence to long-term therapies: Evidence for actionEur J Cardiovasc Nurs20032323323

4 

E SabateAdherence to long - term therapies: evidence for actionGenevaWorld Health Organization2003

5 

P Theofilou, Saborit A ReyesPredictors of asthma treatment adherenceJ Psychol Psychother2012312

6 

P TheofilouFactors affecting level of compliance in chronic patientsJ Int Med2011212

7 

ER Levensky, WT O'Donohue, T WilliamPatient adherence and nonadherence to treatmentsWT O'Donohue, ER LevenskyPromoting treatment adherence: A practical handbook for health care providersThousand Oaks, CASage Publications, inc.2006314

8 

P TheofilouImproved quality of life, functional and emotional status: the doctor patient relationshipJ Primary Health Care2011112

9 

P TheofilouInterventions to support medication adherence in individuals with chronic disease: the role of health professionalsJ Commun Med Health Educat[In press]

10 

P TheofilouIdentifying risk factors associated with compliance to medication in elderly kidney transplant patientsJ Transplant Technol Res2012212

11 

RP AustinPolypharmacy as a risk factor in the treatment of type 2 diabetesDiabet Spectrum200619136

12 

MD Murray, J Wu, W TuHealth literacy predicts medication adherenceClin Pharmacol Ther200475P76P76

13 

DT Gold, IM Alexander, MP EttingerHow can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapyAnn Pharmacother200640114350

14 

LR Chia, EA Schlenk, J Dunbar-JacobEffect of personal and cultural beliefs on medication adherence in the elderlyDrugs Aging200623191202

15 

P TheofilouThe relation of social support to mental health and locus of control in chronic kidney diseaseJ Renal Nurs201241822

16 

P TheofilouNon - compliance with medical regimen in haemodialysis treatment: a case studyCase Rep Nephrol201114

17 

P TheofilouMajor depression in women diagnosed with breast cancerJ Int Med[In press]

18 

P TheofilouQuality of life and mental health in haemodialysis and peritoneal dialysis patients: the role of health beliefsInt Urol Nephrol20124424553

19 

P Theofilou, Saborit A ReyesHealth locus of control and diabetes adherenceJ Psychol Psychother2012312

20 

P TheofilouThe impact of personality traits on quality of life in patients diagnosed with breast cancerJ Women Health Care2011112

21 

D Bransfield, J Horiot, M BoneHigh compliance with fluoride treatment by patients irradiated for head and neck tumors: A theoretical interpretationJ Psychosoc Oncol198644351

22 

MR DiMatteo, DD DiNicolaAcheving patient complianceElmsford, NYPergamon1982

23 

J Itano, P Tanabe, J LumCompliance and noncompliance in cancer patientsProgr Clin Biol Res198312048395

24 

J Richardson, G Marks, C JohnsonPath model of multidimensional compliance with cancer therapyHealth Psychol19876183207

25 

A Ayres, P Hoon, J FranzoniInfluence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patientsJ Psychosom Res199438393402

26 

DL Sackett, BR HaynesCompliance with therapeutic regimensBaltimoreJohns Hopkins University Press1976

27 

JE Milam, JL Richardson, G MarksThe roles of dispositional optimism and pessimism in HIV disease progressionPsychol Health20041916781

28 

L Lorenc, A BranthwaiteAre older adults less compliant with prescribed medication than younger adults?Br J Clin Psychol19933248592

29 

R Menzies, I Rocher, B VissandjeeFactors associated with compliance in treatment of tuberculosisTuber Lung Dis199374327

30 

CT Wai, ML Wong, S NgUtility of the health belief model in predicting compliance of screening in patients with chronic hepatitis BAliment Pharmacol Ther200521125562

31 

MR Wild, HM Engleman, NJ DouglasCan psychological factors help us to determine adherence to CPAP? A prospective studyEur Respir J2004244615

32 

F Viller, F Guillemin, S BrianconCompliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal studyJ Rheumatol199926211422

33 

RH Didlake, K Dreyfus, RH KermanPatient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplantsTransplant Proc198820639

34 

PA Frazier, SH Davis-Ali, KE DahlCorrelates of noncompliance among renal transplant recipientsClin Transplant199485507

35 

RP Hertz, AN Unger, MB LustikAdherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insuranceClin Ther200527106473

36 

YS Kim, S Sunwoo, HR LeeDeterminants of non-compliance with lipid-lowering therapy in hyperlipidemic patientsPharmacoepidemiol Drug Saf200211593600

37 

CG McLane, SJ Zyzanski, SA FlockeFactors associated with medication noncompliance in rural elderly hypertensive patientsAm J Hypertens199582069

38 

M Monane, RL Bohn, JH GurwitzCompliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and raceAm J Public Health19968618058

39 

SA Norman, KM Marconi, GW SchezelBeliefs, social normative influences, and compliance with antihypertensive medicationAm J Prev Med19851107

40 

RT Schweizer, M Rovelli, D PalmeriNoncompliance in organ transplant recipientsTransplantation1990493747

41 

V Senior, TM Marteau, J WeinmanSelf - reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptionsCardiovasc Drugs Ther20041847581

42 

E Shaw, JG Anderson, M MaloneyFactors associated with noncompliance of patients taking antihypertensive medicationsHosp Pharm19953020132067

43 

S Shea, D Misra, MH EhrlichCorrelates of nonadherence to hypertension treatment in an inner-city minority populationAm J Public Health199282160712

44 

JA Sirey, ML Bruce, GS AlexopoulosStigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherencePsychiatr Serv200152161520

45 

D Buck, A Jacoby, GA BakerFactors influencing compliance with antiepileptic drug regimesSeizure199768793

46 

O Balbay, AN Annakkaya, P ArbakWhich patients are able to adhere to tuberculosis treatment? A study in a rural area in the northwest part of TurkeyJpn J Infect Dis2005581528

47 

JS Benner, RJ Glynn, H MogunLong - term persistence in use of statin therapy in elderly patientsJAMA200228845561

48 

J Okuno, H Yanagi, S TomuraCompliance and medication knowledge among elderly Japanese home-care recipientsEur J Clin Pharmacol1999551459

49 

ME Caban, MA Nosek, D GravesBreast carcinoma treatment received by women with disabilities compared with women without disabilitiesCancer20029413916

50 

SG Diab, RM Elledge, GM ClarkTumor characteristics and clinical outcome of elderly women with breast cancerJ Natl Cancer Inst2000925506

51 

X Du, JS GoodwinIncrease of chemotherapy use in older women with breast carcinoma from 1991 to 1996Cancer2001927307

52 

X Du, JS GoodwinPatterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims dataJ Clin Oncol200119145561

53 

G Freyer, AC Braud, P ChaibiDealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the ‘Observatory on Elderly Patients'Ann Oncol2006172116

54 

J Golledge, JE Wiggins, MJ CallamAge-related variation in the treatment and outcomes of patients with breast carcinomaCancer20008836974

55 

J Mitchell, DR Lannin, HF MathewsMS SwansonReligious beliefs and breast cancer screeningJ Womens Health (Larchmt)20021190715

56 

PB PeeleLA SiminoffY XuPM RavdinDecreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk informationMed Decis Making2005253017

57 

L WyldDK GargID KumarStage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelinesBr J Cancer200490148691

58 

EA GrunfeldAJ RamirezEJ MaherChemotherapy for advanced breast cancer: what influences oncologists' decision-making?Br J Cancer20018411728

59 

LK DunnwaldMA RossingCI LiHormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patientsBreast Cancer Res20079R6R6

60 

L DowneyR LivingstonA StopeckDiagnosing and treating breast cancer in elderly women: a call for improved understandingJ Am Geriatr Soc200755163644

61 

LF HutchinsJM UngerJJ CrowleyUnderrepresentation of patients 65 years of age or older in cancer-treatment trialsN Engl J Med199934120617

62 

JS BennerRJ GlynnH MogunLong - term persistence in use of statin therapy in elderly patientsJAMA200228845561

63 

PR ChizzolaAJ MansurPL da LuzCompliance with pharmacological treatment in outpatients from a Brazilian cardiology referral centerSao Paulo Med J1996114125964

64 

P TheofilouMedication adherence in Greek hemodialysis patients: The contribution of depression and health cognitionsInt J Behav Med201218

65 

SD JesteTL PattersonBW PalmerCognitive predictors of medication adherence among middle-aged and older outpatients with schizophreniaSchizophr Res2003634958

66 

MD MurrayJ DarnellM WeinbergerFactors contributing to medication noncompliance in elderly public housing tenantsDrug Intell Clin Pharm19862014652

67 

T NikolausW KruseM BachElderly patients' problems with medication. An in-hospital and follow-up studyEur J Clin Pharmacol1996492559

68 

J OkunoH YanagiS TomuraIs cognitive impairment a risk factor for poor compliance among Japanese elderly in the community?Eur J Clin Pharmacol20015758994

69 

RB StewartGJ CaranasosMedication compliance in the elderlyMed Clin North Am198973155163

70 

AJ ApterRC BostonM GeorgeModifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and whiteJ All Clin Immunol2003111121926

71 

AJ GhodsD NasrollahzadehNoncompliance with immunnosuppressive medications after renal transplantationExp Clin Transplant200313947

72 

A YavuzM TuncerO ErdoganIs there any effect of compliance on clinical parameters of renal transplant recipients?Transplant Proc2004361201

73 

R HorneJ WeinmanPatients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illnessJ Psychosom Res19994755567

74 

FA KaonaM TubaS SiziyaAn assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatmentBMC Public Health2004296868

75 

SA NormanKM MarconiGW SchezelBeliefs, social normative influences, and compliance with antihypertensive medicationAm J Prev Med19851107

76 

FJ SpikmansJ BrugMM DovenWhy do diabetic patients not attend appointments with their dietitian?J Hum Nutr Diet2003161518

77 

CS StilleyS SereikaMF MuldoonPsychological and cognitive function: predictors of adherence with cholesterol lowering treatmentAnn Behav Med20042711724

78 

CT WaiML WongS NgUtility of the health belief model in predicting compliance of screening in patients with chronic hepatitis BAliment Pharmacol Ther200521125562

79 

MR DiMatteoPatient adherence to pharmacotherapy: the importance of effective communicationFormulary19953059686012605605

80 

H KyngasT LahdenperaCompliance of patients with hypertension and associated factorsJ Ad Nurs1999298329

81 

KT Ashing-GiwaG PadillaJ TejeroUnderstanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivorsPsychooncology20041340828

82 

C OsborneGV OstirX DuThe influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancerBreast Cancer Res Treat200593417

83 

CE ConnellyCompliance with outpatient lithium therapyPerspect Psychiatr Care1984224450

84 

JJ EllisSR EricksonJG StevensonSuboptimal statin adherence and discontinuation in primary and secondary prevention populationsJ Gen Intern Med20041963845

85 

S PonnusankarM SurulivelrajanN AnandamoorthyAssessment of impact of medication counseling on patients' medication knowledge and compliance in an outpatient clinic in South IndiaPatient Educ Couns2004545560

86 

E ShawJG AndersonM MaloneyFactors associated with noncompliance of patients taking antihypertensive medicationsHosp Pharm19953020132067

87 

S Choi-KwonSU KwonJS KimCompliance with risk factor modification: early-onset versus late-onset stroke patientsEur Neurol20055420411

88 

RC KaplanNC BhalodkarEJ BrownRace, ethnicity, and sociocultural characteristics predict noncompliance with lipid - lowering medicationsPrev Med200439124955

89 

C Swett JrJ NoonesFactors associated with premature termination from outpatient treatmentHosp Commun Psychiatry19894094751

90 

AJ ApterST ReisineG AffleckAdherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differencesAm J Respir Crit Care Med199815718107

91 

JS BennerRJ GlynnH MogunLong-term persistence in use of statin therapy in elderly patientsJAMA200228845561

92 

G BerghoferF SchmidlS RudasPredictors of treatment discontinuity in outpatient mental health careSoc Psychiatry Psychiatr Epidemiol20023727682

93 

AJ GhodsD NasrollahzadehNoncompliance with immunnosuppressive medications after renal transplantationExp Clin Transplant200313947

94 

L Hernandez-RonquilloJF Tellez-ZentenoJ Garduno-EspinosaFactors associated with therapy noncompliance in type-2 diabetes patientsSalud Publica Mex2003451917

95 

P MishraEH HansenS SabroeSocio-economic status and adherence to tuberculosis treatment: a case-control study in a district of NepalInt J Tuberc Lung Dis2005911349

96 

Congressional Budget OfficePrescription drug coverage and medicare's fiscal challenges2003http://www.cbo.gov/showdoc.cfm?index=4159&sequence=0Accessed: 1 March 2007

97 

TO LimBA NgahThe Mentakab hypertension study project. Part II - why do hypertensives drop out of treatment?Singapore Med J19913224951

98 

SA NormanKM MarconiGW SchezelBeliefs, social normative influences, and compliance with antihypertensive medicationAm J Prev Med19851107

99 

RP PatalSD TaylorFactors affecting medication adherence in hypertensive patientsAnn Pharmacother200236405

100 

CS StilleyS SereikaMF MuldoonPsychological and cognitive function: predictors of adherence with cholesterol lowering treatmentAnn Behav Med20042711724

101 

MJ LiuH HawkST GershmanThe effects of a National Breast and Cervical Cancer Early Detection Program on social disparities in breast cancer diagnosis and treatment in MassachusettsCancer Causes Control2005162733

102 

A DowningK PrakashMS GilthorpeSocioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancerBr J Cancer20079683640

103 

RH DidlakeK DreyfusRH KermanPatient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplantsTransplant Proc198820639

104 

LR RaizKM KiltyML HenryMedication compliance following renal transplantationTransplantation199968515

105 

LK ThomasRG SargentPC MichelsIdentification of the factors associated with compliance to therapeutic diets in older adults with end stage renal diseaseJ Ren Nutr200111809

106 

YF YuMB NicholAP YuPersistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid programValue Health20058495505

107 

JR ButterworthLM BanfieldTH IqbalFactors relating to compliance with a gluten-free diet in patients with coeliac disease: comparison of white Caucasian and South Asian patientsClin Nutr200423112734

108 

KL DominickYM GolightlyHB BosworthRacial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritisEthn Dis20051511622

109 

JE Leggat JrSM OrzolTE Hulbert - ShearonNoncompliance in hemodialysis: predictors and survival analysisAm J Kidney Dis19983213945

110 

M MonaneRL BohnJH GurwitzCompliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and raceAm J Public Health19968618058

111 

JL OpolkaKL RascatiCM BrownRole of ethnicity in predicting antipsychotic medication adherenceAnn Pharmacother20033762530

112 

RT SchweizerM RovelliD PalmeriNoncompliance in organ transplant recipientsTransplantation1990493747

113 

FJ SpikmansJ BrugMM DovenWhy do diabetic patients not attend appointments with their dietitian?J Hum Nutr Diet2003161518

114 

N MaloneyM KochD ErbImpact of race on breast cancer in lower socioeconomic status womenBreast J2006125862

115 

VL ShaversLC HarlanJL StevensRacial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35Cancer20039713447

116 

M DiMatteoH LepperTW CroghanDepression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherenceArch Int Med200016021017

117 

A AyresP HoonJ FranzoniInfluence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patientsJ Psychosom Res199438393402

118 

SM MillerMonitoring and blunting: Validation of a questionnaire to assess styles of information seeking under threatJ Pers Soc Psychol19875234553

119 

CS CarverRG SmithMH AntoniOptimistic personality and psychosocial well-being during treatment predict psychosocial well-being among long-term survivors of breast cancerHealth Psychol20052450816

120 

JE Epping-JordanBE CompasDM OsowieckiPsychological adjustment in breast cancer: Processes of emotional distressHealth Psychol19991831526

121 

G GodinJ CoteH NaccachePrediction of adherence to antiretroviral therapy: A one-year longitudinal studyAIDS Care200517493504

122 

CS CarverJM LehmanMH AntoniDispositional pessimism predicts illness-related disruption of social and recreational activities among breast cancer patientsJ Pers Soc Psychol20038481321

123 

ME Garay-SevillaLE NavaJM MalacaraAdherence to treatment and social support in patients with non-insulin dependent diabetes mellitusJ Diabet Complicat19959816

124 

HA KyngasCompliance of adolescents with asthmaNurs Health Sci19991195202

125 

H KyngasPredictors of good compliance in adolescents with epilepsySeizure20011054953

126 

W LofflerR KilianM ToumiSchizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatmentPharmacopsychiatry20033610512

127 

L LorencA BranthwaiteAre older adults less compliant with prescribed medication than younger adults?Br J Clin Psychol19933248592

128 

NC MilasMP NowalkL AkpeleFactors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease StudyJ Am Diet Assoc1995951295300

129 

MA SeoSK MinDevelopment of a structural model explaining medication compliance of persons with schizophreniaYonsei Med J20054633140

130 

AL StantonDeterminants of adherence to medical regimens by hypertensive patientsJ Behav Med19871037794

131 

A StrombergA BrostromU DahlstromFactors influencing patient compliance with therapeutic regimens in chronic heart failure: A critical incident technique analysisHeart Lung19992833441

132 

LK ThomasRG SargentPC MichelsIdentification of the factors associated with compliance to therapeutic diets in older adults with end stage renal diseaseJ Ren Nutr200111809

133 

CI VoilsDC SteffensEP FlintSocial support and locus of control as predictors of adherence to antidepressant medication in an elderly populationAm J Geriatr Psychiatry20051315765

Abstract views:
4904

Views:
PDF
745
HTML
456

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2012 Paraskevi Theofilou, Helen Panagiotaki

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185